medigraphic.com

2017, Number 2

<< Back Next >>

Rev Hematol Mex 2017; 18 (2)

Unusual manifestation of active multiple myeloma. Acquired dysfibrinogenemia and inhibitor of factor V

Suárez-González L, Sanabria-Alba L, García D, Paoletti M, Pepe A

Language: Spanish
References: 22
Page: 92-98
PDF size: 265.93 Kb.


ABSTRACT

Multiple myeloma is the second malignant hemopathy (10%), followed by non-Hodgkin lymphomas. The presentation of the diseases uses to be related to signs CRAB (hypercalcemia, renal failure, anemia and bone lesions) and in rare occasions may be manifested with bleeding due to associated coagulopathies, as the case of dysfibrinogenemia and factor V inhibitor of coagulation. This article describes a case derived to our consultation for study of anemia secondary to bleeding and literature is reviewed.


REFERENCES

  1. Paiva B, Vidriales MB, Cervero J, Mateo G, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008;112(10):4017-23.

  2. Paiva B, Almeida J, Perez-Andres M, Mateo G, et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom 2010;78(4):239-52.

  3. Paiva B, Martinez-Lopez J, Vidriales MB, Mateos MV, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 2011;29(12):1627-33.

  4. Paiva B, Montalbán MA, Puig N, Cordon L, et al. Clinical significance of sensitive flow-MRD monitoring in elderly multiple myeloma patients on the Pethema/GEM2010MAS65 Trial. Blood 2014;124(21):3390.

  5. Perez-Persona E, Vidriales MB, Mateo G, García-Sanz R, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007;110(7):2586-92.

  6. Yu-Tzu T, Anderson KC. A new era of immune therapy in multiple myeloma. Blood 2016;128(3):318-319.

  7. Rajkumar S, Paiva B, Anderson K, Durie B, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17(8):328-46.

  8. Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood 2015;125(20):3049-3055.

  9. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364(11):1046-60.

  10. Wallace MR, SR Simon, WB Ershler. Hemorrhagic diathesis in multiple myeloma. Acta Haematol 1984;72:340-342.

  11. Colwell NS, Tollefsen DM, Blinder MA. Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder. Br J Haemat 1997;97:219-226.

  12. Brennan SO, Davis RL, Lowen R, et al. Deletion of five residues from the coiled coil of fibrinogen (Bβ Asn167_Glu- 171del) associated with bleeding and hypodysfibrinogenemia. Haematologica 2009;94(4):585-588.

  13. Hanss M, Pouymayou C, Blouch MT, et al. Haematologica 2011;96(8):1226-1228.

  14. Gralnick HR, Connaghan DG. Hereditary abnormalities of fibrinogen. En: Beutler E, Lichtman MA, Coller BS, Kipps TJ, editors. Wiliams Hematology. 5th ed. New York: McGraw- Hill, 1995;1439.

  15. Bohler A, Redondo M, Lmmle B. Increased thrombin time in a patient with multiple myeloma. Ther Umsch 1999;56:491-494.

  16. Palmer RN, Rick ME, Rick PD. Circulating heparan sulfate anticoagulant in a patient with a fatal bleeding disorder. N Engl J Med 1984;310:1696-1699.

  17. Chapman GS, George CB, Danley DL. Heparin-like anticoagulant associated with plasma cell myeloma. AJCP 1985;83:764-766.

  18. Khoory MS, Nesheim ME, Bowie EJ. Circulating heparan sulfate proteoglycan from a patient with a plasma cell disorder. J Clin Invest 1980;65:666-674.

  19. Leckner H. Hemostasis abnormalities associated with dysproteinemias. Semin Hematol 1973;10:125-133.

  20. Butler WM, Baldwin MPE. Prolongation of thrombin and reptilase times in patients with amyloidosis and acquired factor X deficiency. Southern Med J 1984;77:648-651.

  21. Sari I, Erkurt MA, Ifran A, et al. Multiple myeloma presenting with acquired factor VIII inhibitor. Int J Hematol 2009;90:166. doi:10.1007/s12185-009-0363-9.

  22. Lewandowski K, et al. IgG monoclonal immunoglobulin (M-protein) as factor V inhibitor in multiple myeloma patient: Case report and discussion. J Clin Cell Immunol 2016;7:2.




2020     |     www.medigraphic.com